{"filing":{"accession_number":"0001193125-26-231040","cik":"0001213037","ticker":null,"company_name":"Cardiff Oncology, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"crdf-20260519.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526231040/crdf-20260519.htm"},"classifications":[{"id":189,"accession_number":"0001193125-26-231040","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"Cardiff Oncology filed a lawsuit against Nerviano Medical Sciences in U.S. District Court for the Southern District of California seeking injunctive relief and declaratory judgment regarding an alleged material breach of a license agreement for onvansertib. The dispute centers on patent inventorship obligations and continuation patent applications, with Cardiff disputing NMS's breach allegations. This is a material litigation event that would affect investor assessment of the company's ability to maintain its license rights and product development.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:20:50.239694+00:00","company_name":"Cardiff Oncology, Inc.","ticker":null,"filing_date":"2026-05-19"}]}